MBBS, MD, FRCP
Chief Executive Officer
Dr. Lau is the Chief Executive Officer of Axis Therapeutics. He is also the Chief Executive Officer and Chairman of the Board of Athenex, Inc. Dr. Lau brings over 20 years of leadership experience in both scientific and business management to Axis Therapeutics. He previously served as Chairman and CEO of Ribapharm Inc., and oversaw Ribapharm’s initial public offering in 2002. Prior to Ribapharm, he served as SVP and Head of Research and Development for ICN Pharmaceuticals Inc. Prior to joining ICN, Dr. Lau served as the Senior Director of Antiviral Therapy Research at Schering-Plough. Dr. Lau has contributed more than 200 scientific publications, editorials/reviews and chapters in peer reviewed scientific journals and has edited two books. He was a former Managing Director at Roth Capital Partners and a Director of the Board of Chelsea Therapeutics, serving as the Chair of the Audit and Risk Management Committee as well as the Corporate Governance Committee. He is also an honorary professor/adjunct professor of the University of Hong Kong, Hong Kong Polytechnic University and Chongqing Southwestern Hospital, and a member of the Advisory Board of the School of Biomedical Sciences of the Chinese University of Hong Kong. Dr. Lau received his medical degree, or MBBS, and medical doctorate degree, or M.D., from the University of Hong Kong. He is also a Fellow of the Royal College of Physicians.